Home > Back to Publisher > Report Information

Chinese Pharmaceutical Market 2012-2022

Visiongain
December 6, 2011
158 Pages - SKU: VSG6777454

Abstract Table of Contents Related Reports

Countries covered: China

Where is the pharma market in China heading? Visiongain's report shows you its potential revenues to 2022, discussing opportunities and developments.

Discover sales predictions at overall market and submarket levels. Our study gives you business research, analysis and opinion for drug sales in China. Find data and trends there.

See how Chinese submarkets can perform to 2022 - patented brands, generics, OTC products, traditional medicines, anti-infectives, vaccines, cardiovascular/cerebrovascular, alimentary/metabolic, cancer and CNS drugs. You view potential revenues, with discussions.

How will governmental reform of the healthcare system affect the pharmaceutical industry? Will patented branded products achieve greater market penetration this decade?

Opportunities multiply. The government's Healthy China 2020 plan will mean up to $1.4 trillion invested. See the effects of rising purchase power and widening medical coverage, discovering prospects from 2012. You find information, calculations and views in this report.

Medical R&D in China is gaining prominence. Assess the trends behind its emergence as a biopharmaceutical hub, reviewing progress in outsourced research and manufacturing.

The report discusses many domestic companies, such as China National Biotec Group, Sinopharm, WuXi AppTec, Sinovac Biotech and Beijing Pharmaceutical Group. Biopharma industry is flourishing.

View activities of multinationals too, including Pfizer, Sanofi, Bayer, AstraZeneca, Roche, Novartis, GSK, Merck, Eli Lilly and Novo Nordisk. This is the country to watch for developments in healthcare. Our investigation shows you why.

Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You can find answers now in our work.

Revenue forecasts, market shares, developmental trends, discussions and interviews

In the report, you find revenue forecasting, growth rates, market shares, qualitative analyses (incl. SWOT and STEP), opinions and news. You receive 72 tables and charts and two research interviews.

Advantages of Chinese Pharmaceutical Market 2012-2022 for your work

In particular, this study gives you the following knowledge and benefits:

Find revenue predictions to 2022 for the overall Chinese pharma market and submarkets, seeing revenue growth
Read sections on 40 prominent companies there, viewing developments in biotechnology and other aspects of medicine
Investigate competition and opportunities influencing sales results
Find out what will stimulate and restrain the market, affecting its growth
See emerging trends in biopharma R&D, contract research and manufacturing
Appraise therapeutic and commercial needs, as well as healthcare policy
View opinions from our survey of authorities on the sector.

There, you receive a distinctive mix of quantitative and qualitative work with independent predictions. We analyse activities and events, helping you to stay ahead.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. This password will be set up for single user and departmental licenses and will be emailed out to the client at the same time as the report

Additional Information

Report Excerpt

4.5 Central Nervous System Diseases Market 2012-2022

Central nervous system (CNS) disorders are currently a minor part of the market compared with the four therapeutic classes surveyed above. China spends less than many other emerging markets in Asia, including India and South Korea, on treatments for these disorders. However, the CNS market is likely to increase in importance, in line with its key position in Western markets, as China’s disease burden comes to resemble that of the other major industrialized countries. In particular, these nations face a growing burden of neurodegenerative disease, which is one of the major R&D foci for the industry. China’s ageing population (180 million of the population will be over 65 years of age by 2020) means it will face the same challenges as the US, Europe and Japan in this area. As a result, CNS products are expected to become more relevant to the Chinese market. Several Western CNS products have been launched over the past few years, with much attention given to Keppra (levetiracetam), an epilepsy treatment launched in 2007, Champix (varenicline), a smoking cessation treatment launched in 2008, and Invega (paliperidone), a schizophrenia treatment launched in 2009.

Companies Listed

Abbott Laboratories
Acambis
Agilent Technologies
American California Pharmaceutical Group
Anhui BBCA Biochemical
AppTech Laboratory Services
Ascletis
Asian Cancer Research Group
AstraZeneca
Aurobindo Pharma
AXM Pharma
Bayer Schering Pharma
Beijing Bio-Ekon Biotechnology
Beijing Double-Crane Pharmaceutical Business
Beijing GP Medical Technologies
Beijing Haiyan Pharmaceutical Company
Beijing Pharmaceutical Group
Beijing Shuanglu
Beijing Tiantan Biological Products
Beijing Union Medical College Hospital
Beijing University
Beijing Wandong Medical Equipment
Beijing Yuande Bio-Medical Engineering
BGI (formerly Beijing Genomics Institute)
Biocon
BioDura
BioMarin Pharmaceutical
Bioton
BMP Sandstone
Bristol-Myers Squibb
Broad Institute
Buchang Pharmaceutical
C&O Pharmaceutical Technology Holdings
Cai Zhi Lin Pharmacies
Cancer Therapeutics
Charles River Laboratories
China Aoxing
China Chain Stores and Franchise Association (CCSFA)
China Medical Technologies
China National Biotec Group
China National Pharmaceutical Corporation (Sinopharm)
China Nepstar Chain Drugstore
China Pharmaceutical Group (China Pharma)
China Sky One Medical
ChinaBio Therapeutics
Chinese Academy of Medical Sciences
Chinese Academy of Sciences
Chinese Diabetes Society
Chongqing Taiji Industry Group
Chongqing Tongjunge
Cipla
Cord Blood America
Covance
Crown Bioscience
Crucell Biotechnology
CSPC Pharmaceutical Group
CSPC Zhongrun
Cumencor Pharmaceuticals
Denosim
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Eisai
Eli Lilly
European Medicines Agency (EMEA/EMA)
Excel PharmaStudies
FeRx
Food and Drug Administration (FDA, US)
Frontage Laboratories
GenScript
Genzyme Corporation
GlaxoSmithKline
Goldman Sachs Group
Greater China Corporation
Guangdong Province People's Hospital
Guangzhou Medical University
Guangzhou Pharmaceutical Company
Guangzhou Pharmaceutical Holdings
Habin Tian Di Ren Medical Science and Technology
Hangzhou Sanofi-Synthelabo Minsheng
Hangzhou Zhongmei Huadong Pharmaceutical
Harbin Pharmaceutical Group
HD Biosciences
Hebei Pharmaceutical Group
Huadong Medicine Company
Hualan Biological Engineering
Hutchison MediPharma
Institute for BioMedical Research (Shanghai)
International Diabetes Foundation
Introgen Therapeutics
Ivax Corporation
Jian Min Pharmacies
Jiangsu Haici Biological Pharmacy Company
Jiangsu New Medicine Research Institution
Jiangsu Walvax Biotech
Johnson & Johnson
Knoll
LEAD Pharmaceuticals
LG Life Sciences
Lundbeck
Merck & Co.
MicuRx Pharmaceuticals
Mindray Medical International
Ministry of Commerce (China)
Ministry of Science and Technology (China)
Minsheng Pharmaceutical
Mirahi Biotech
Nanjing Hailing National Engineering Research Center
Nanjing Hailing Pharmaceutical Company
National Center for Drug Screening (China)
New England Journal of Medicine
Northeast General Pharmaceutical
Northeast Pharmaceutical Group (NEPG)
NorthEast Pharmacy Chain
NovaMed Pharmaceuticals
Novartis
Novartis China
Novo Nordisk
Nycomed Amersham
Organization for Economic Cooperation and Development (OECD)
Patheon
Pfizer
Piramal Healthcare Solutions
PlaNrt Finance
Provincial Institute for the Control of Pharmaceutical and Biologic Products (China)
Qilu Pharmaceutical
QRxPharma
Roche
Sandoz (part of Novartis)
Sanjing Pharmaceutical
Sanofi
Shandong Dong-E E-Jiao
Shanghai Zhong Hua Pharmaceutical Factory (Jiang Qiao Branch)
Shanghai ChemExplorer
Shanghai Haini Pharmaceutical Company
Shanghai Huai Hai Pharmaceutical Factory
Shanghai Institute for Biological Sciences
Shanghai Institute of Materia Medica
Shanghai Jiao Tong University
Shanghai No. 6 Pharmaceutical Factory
Shanghai Pharmaceutical Group (SPGC)
Shanghai Qisheng
Shanghai Schering-Plough
Shanghai Sunve Pharmaceutical
Shanghai Xin Hua Lian Pharmaceutical
Shenzhen Neptunus Interlong Bio-Technique
Shenzhen SiBiono GeneTech
Shijiazhuang Pharmaceutical Group
Shire Pharmaceuticals
SiBiono
Sichuan Hairong Pharmaceutical Company
Sicor Pharmaceuticals
SiniWest Holdings
Sino-American Kunming Baker Norton Pharmaceutical
Sinopharm
Sinovac Biotech (Beijing Kexing Bioproducts)
Solvay Pharmaceuticals
Southwest Pharmaceutical
State Food and Drug Administration (SFDA)
State Key Lab of Respiratory Disease
Sundia Meditech
Sunway Biotech
Suzhou Novartis Pharma Technology
Taiji Group
Takeda Pharmaceutical
Tangshan Yian Bioengineering
Teva Pharmaceutical Industries
Thermo Fisher Scientific
Tianjin International Joint Academy of Biotechnology and Medicine
Tianjin Jin Yao Group
Tianjin Medical University Cancer Hospital
Tianjin Pharmaceutical Factory
Tianjin Pharmaceuticals Group Corporation
Tianjin Takeda Pharmaceuticals
Tonghua Dongbao
Tongrentang Pharmaceutical
Tsinghua University
UNICEF
United Pharmatech
Vertex Pharmaceuticals
Weisheng Pharmaceutical
Working Group on Obesity in China
World Health Organization (WHO)
World Trade Organization (WTO)
Wuhan National Bioindustry Base Construction
WuXi AppTec
WuXi PharmaTech
Wyeth (now part of Pfizer)
Xian-Janssen Pharmaceuticals
Yangtze River Pharmaceutical Group
Yunnan Walvax BiotechJiangsu Pharmaceutical Company
Zensun (Shanghai) Sci & Tech
Zhejiang Huahai Pharmaceuticals
Zhejiang Medicine
Zhejiang Tianyuan
Zhongnuo
Zydus Cadila

1. Executive Summary: 1.1 China: Pharmaceutical Market Review; 1.2 Contents of this Report; 1.3 Research and Analysis Methods
2. Chinese Pharmaceutical Market: An Overview: 2.1 China: National Overview; 2.2 From Maoism to Market: Chinese Healthcare Since World War II; 2.3 The Rise of the Chinese Pharmaceutical Market; 2.4 Healthy China 2020: 'Unprecedented in Human History'; 2.5 Demography and Disease Burden in China; 2.6 Other Aspects of the Chinese Market
3. The Chinese Pharmaceutical Market, 2012-2022: 3.1 Chinese Pharmaceutical Market: Forecast, 2012-2022; 3.2 The Product Mix in China, 2010; 3.3 The Product Mix in China, 2012-2022; 3.4 Prescribed Patented Brands: Forecast, 2012-2022; 3.5 Prescribed Generics: Forecast, 2012-2022; 3.6 OTC Products: Forecast, 2012-2022; 3.7 TCM Products: Forecast, 2012-2022
4. Leading Therapeutic Areas in the Chinese Market, 2012-2022: 4.1 Anti-Infectives Market, 2012-2022; 4.2 Cancer Treatments Market, 2012-2022; 4.3 Cardiovascular/Cerebrovascular Market, 2012-2022; 4.4 Alimentary and Metabolic Diseases Market, 2012-2022; 4.5 Central Nervous System Diseases Market, 2012-2022; 4.6 Vaccines Market, 2012-2022; 4.7 Other Therapeutic Classes Market, 2012-2022
5. China as a Pharmaceutical Hub, 2012-2022: 5.1 China as a Manufacturing Hub; 5.2 China as a Research Hub; 5.3 China as a Biotechnology Hub; 5.4 China as a Pharmaceutical Hub: Conclusions
6. Key Domestic Players in the Chinese Market, 2012: 6.1 Fragmentation and Consolidation Among Chinese Companies; 6.2 Summary of Leading Domestic Companies; 6.3 China National Pharmaceutical Corporation (Sinopharm); 6.4 China National Biotec Group (CNBG); 6.5 WuXi AppTec; 6.6 CSPC Pharmaceutical Group; 6.7 Beijing Pharmaceutical Group; 6.8 Shanghai Pharmaceutical Group (SPGC); 6.9 Yangtze River Pharmaceutical Group; 6.10 Tianjin Pharmaceuticals Group Corporation (TJPC); 6.11 Taiji Group; 6.12 C&O Pharmaceutical Technology Holdings; 6.13 Harbin Pharmaceutical Group Holding Company; 6.14 Guangzhou Pharmaceutical Holdings; 6.15 Sinovac Biotech (Beijing Kexing Bioproducts); 6.16 Tongrengtang Pharmaceutical; 6.17 Buchang Pharmaceutical; 6.18 Northeast Pharmaceutical Group (NEPG); 6.19 China Nepstar Chain Drugstore; 6.20 Zhejiang Huahai Pharmaceuticals; 6.21 Hangzhou Zhongmei Huadong Pharmaceutical; 6.22 Hualan Biological Engineering; 6.23 China Sky One Medical; 6.24 Zensun (Shanghai) Sci & Tech; 6.25 Ascletis; 6.26 Shangdong Dong-E-E-Jiao; 6.27 Mindray Medical International and China Medical Technologies
7. Key Multinational Players in the Chinese Market, 2012: 7.1 Bayer Schering; 7.2 AstraZeneca; 7.3 Pfizer; 7.4 Sanofi; 7.5 Roche; 7.6 Novartis; 7.7 GlaxoSmithKline; 7.8 Merck & Co.; 7.9 Novo Nordisk; 7.10 Eli Lilly; 7.11 Abbott Laboratories; 7.12 Johnson & Johnson; 7.13 Bristol-Myers Squibb; 7.14 Teva Pharmaceutical Industries; 7.15 Takeda
8. The Chinese Pharma Market: Qualitative Analysis: 8.1 Strengths: Government Investment Will Further Expand this Dynamic Market; 8.2 Weaknesses: IP and Regulatory Challenges Remain; 8.3 Opportunities: The Scramble for China; 8.4 Threats: A House Built on Sand?
9. Research Interviews: 9.1 Interview with Dr Derek Lowe, Drug Discovery Expert; 9.2 Interview with Dr Jean-Pierre Wery, President, Crown Bioscience, China
10. Conclusions: 10.1 The Chinese Pharma Market Will Continue to Grow Rapidly; 10.2 Treatments for Chronic Diseases Will Challenge the Anti-Infectives Sector; 10.3 China Will Continue to Grow as a Focus for the Multinational Industry; 10.4 China is Set to be the Most Important Pharmaceutical Market, Despite Weaknesses
List of Tables: Table 2.1 Causes of Mortality in China, 2002; Table 3.1 Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2010-2015; Table 3.2 Chinese Pharmaceutical Market: Revenues ($bn), AGR (%), CAGR (%), 2016-2022; Table 3.3 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2010; Table 3.4 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015; Table 3.5 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2015; Table 3.6 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022; Table 3.7 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2022; Table 3.8 Prescribed Patented Brands Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015; Table 3.9 Prescribed Patented Brands Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022; Table 3.10 Prescribed Generics Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015; Table 3.11 Prescribed Generics Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022; Table 3.12 OTC Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015; Table 3.13 OTC Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022; Table 3.14 TCM Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015; Table 3.15 TCM Products Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022; Table 4.1 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2010; Table 4.2 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015; Table 4.3 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2015; Table 4.4 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022; Table 4.5 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2022; Table 4.6 Anti-Infectives Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015; Table 4.7 Anti-Infectives Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022; Table 4.8 Oncology Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015; Table 4.9 Oncology Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022; Table 4.10 Cardiovascular/Cerebrovascular Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015; Table 4.11 Cardiovascular/Cerebrovascular Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022; Table 4.12 Alimentary/Metabolic Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015; Table 4.13 Alimentary/Metabolic Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022; Table 4.14 CNS Diseases Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015; Table 4.15 CNS Diseases Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022; Table 4.16 Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015; Table 4.17 Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022; Table 4.18 Other Therapeutic Classes Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2010-2015; Table 4.19 0ther Therapeutic Classes Market: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2016-2022; Table 8.1 Strengths and Weaknesses in the Chinese Pharma Market, 2012-2022; Table 8.2 Opportunities and Threats in the Chinese Pharma Market, 2012-2022
List of Figures: Figure 2.1 Causes of Mortality in China, 2002; Figure 3.1 Chinese Pharmaceutical Market: Revenues ($bn), 2010-2015; Figure 3.2 Chinese Pharmaceutical Market: Revenues ($bn), 2016-2022; Figure 3.3 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2010; Figure 3.4 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), 2010-2015; Figure 3.5 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2015; Figure 3.6 Chinese Pharmaceutical Market Breakdown by Sector: Revenues ($bn), 2016-2022; Figure 3.7 Chinese Pharmaceutical Market, Breakdown by Sector: Revenues ($bn), Market Shares (%), 2022; Figure 3.8 Prescribed Patented Brands Market: Revenues ($bn), 2010-2015; Figure 3.9 Prescribed Patented Brands Market: Revenues ($bn), 2016-2022; Figure 3.10 Prescribed Generics Market: Revenues ($bn), 2010-2015; Figure 3.11 Prescribed Generics Market: Revenues ($bn), 2016-2022; Figure 3.12 OTC Products Market: Revenues ($bn), 2010-2015; Figure 3.13 OTC Products Market: Revenues ($bn), 2016-2022; Figure 3.14 TCM Products Market: Revenues ($bn), 2010-2015; Figure 3.15 TCM Products Market: Revenues ($bn), 2016-2022; Figure 4.1 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2010; Figure 4.2 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), 2010-2015; Figure 4.3 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2015; Figure 4.4 Chinese Pharmaceutical Market Breakdown by Therapeutic Class: Revenues ($bn), 2016-2022; Figure 4.5 Chinese Pharmaceutical Market, Breakdown by Therapeutic Class: Revenues ($bn), Market Shares (%), 2022; Figure 4.6 Anti-Infectives Market: Revenues ($bn), 2010-2015; Figure 4.7 Anti-Infectives Market: Revenues ($bn), 2016-2022; Figure 4.8 Oncology Market: Revenues ($bn), 2010-2015; Figure 4.9 Oncology Market: Revenues ($bn), 2016-2022; Figure 4.10 Cardiovascular/Cerebrovascular Market: Revenues ($bn), 2010-2015; Figure 4.11 Cardiovascular/Cerebrovascular Market: Revenues ($bn), 2016-2022; Figure 4.12 Alimentary/Metabolic Market: Revenues ($bn), 2010-2015; Figure 4.13 Alimentary/Metabolic Market: Revenues ($bn), 2016-2022; Figure 4.14 CNS Diseases Market: Revenues ($bn), 2010-2015; Figure 4.15 CNS Diseases Market: Revenues ($bn), 2016-2022; Figure 4.16 Vaccines Market: Revenues ($bn), 2010-2015; Figure 4.17 Vaccines Market: Revenues ($bn), 2016-2022; Figure 4.18 Other Therapeutic Classes Market: Revenues ($bn), 2010-2015; Figure 4.19 0ther Therapeutic Classes Market: Revenues ($bn), 2016-2022

More China Manufacturing, Packaging & Detailing Reports

China's Pharmaceutical Industry 2011 by China Research and Intelligence Co., Ltd.
This report describes the general development of China’s pharmaceutical industry in aspects of investment, production, sales, import & export, major prices and operations. ...

Research Report on Chinese Human Vaccine Industry, 2012 by China Research and Intelligence Co., Ltd.
The research object of the report is human vaccine apart from animal vaccine. Vaccination is the most economical, effective, safe and convenient way to prevent ...

China Pharmaceutical Industry Research and Forecast to 2016 by AM Mindpower Solutions
EXECUTIVE SUMMARY The present report on “China Pharmaceutical Industry Research and Forecast to 2016” analyzes in detail the pharmaceutical industry environment with market sizing in terms ...

Freedonia Focus on Pharmaceutical Packaging: China by Freedonia Focus
This report discusses pharmaceutical packaging in China for the years 2005 and 2010, with forecasts for 2015. Topics covered include overview of products; market overview; ...

China’s Guidebook for Pharmaceutical Patent Protection by Access China Management Consulting Ltd.
China’s Guidebook for Pharmaceutical Patent Protection is an essential resource for overseas and multinational pharmaceutical companies to achieve a successful patent protection for their intellectual ...

See all reports like this >>

More China Reports

D&B Country RiskLine Report: China by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

Country Report China February 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Country Report China January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

D&B Country Report: China by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Wine - BRIC (Brazil, Russia, India, China) Industry Guide by MarketLine
Datamonitor's Wine - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, ...

See all reports like this >>

Chinese Pharmaceutical Market 2012-2022

Share this report

Other tasks

Research Assistance

Related Markets

Manufacturing, Packaging & Detailing Reports

Free Alert Me service